Analyst firms · Morgan Stanley · DGX
Morgan Stanley DGX price target and rating history
Quest Diagnostics Incorporated (DGX) · Health Care
Morgan Stanley rates Quest Diagnostics Incorporated (DGX) Overweight with a $172 price target, as of its latest action on Dec 17, 2024. It has published 5 rating actions on DGX since August 2021, including 1 upgrade and 0 downgrades.
- Current rating
- Overweight
- Price target
- $172
- Median target, all firms
- Too few
- Actions on DGX
- 5
Morgan Stanley price target on DGX
Every Morgan Stanley rating on DGX
- Dec 17, 2024
- Aug 22, 2022
- Feb 14, 2022
- Dec 17, 2021
- Aug 31, 2021
Questions about Morgan Stanley and DGX
- What is Morgan Stanley's price target for DGX?
- Morgan Stanley's latest stated price target for Quest Diagnostics Incorporated (DGX) is $172, from its action on Dec 17, 2024.
- What is Morgan Stanley's rating on DGX?
- Morgan Stanley rates DGX Overweight, a bullish rating, as of Dec 17, 2024.
- When did Morgan Stanley last change its view on DGX?
- On Dec 17, 2024, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $145 to $172.
More DGX rating histories
All Morgan Stanley ratingsDGX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.